secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001683168-25-008270
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign Q3 revenue $21.6M (+41.6% YoY); raises full-year 2025 guidance
----------------------------------------------------------------------

- Q3 2025 revenue $21.6M (+41.6% YoY); net income $2.22M (+54.2% YoY); diluted EPS $0.04 vs $0.03 YoY.
- Adjusted EBITDA $5.04M (23.3% margin), up 78.1% YoY; pharma patient affordability revenue surged 141.9% to $7.92M.
- Plasma revenue grew 12.4% to $12.86M; exited with 595 plasma centers (down 12 QoQ) and 105 active pharma programs (up 8 QoQ).
- Raises FY2025 guidance: revenue $80.5M–$81.5M (38.7% YoY midpoint), net income $7.0M–$8.0M, Adjusted EBITDA $19.0M–$20.0M.
- Ended quarter with $7.53M unrestricted cash, zero bank debt; opened new 30,000 sq ft customer service center.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316825008270/0001683168-25-008270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316825008270/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-008270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer